Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, Pharmacodynamics, Pharmacokinetics, and Tolerability of Subcutaneous CTI-1601 in Subjects With Friedreich's Ataxia

NCT06447025 is registered in ClinicalTrials.gov with Larimar Therapeutics, Inc. as lead sponsor.

NCT NCT06447025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06447025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, Pharmacodynamics, Pharmacokinetics, and Tolerability of Subcutaneous CTI-1601 in Subjects With Friedreich's Ataxia
Lead sponsor
Larimar Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
January 25, 2024
Completion date
January 31, 2027
Enrollment
85 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

friedreich ataxia